Ipamorelin dosage and routes used in studies
The route is easy to lose when a study number gets repeated.
Volunteer infusions
In the 1999 pharmacokinetic and hormone-response study, healthy male volunteers were studied at five dose levels, with n=8 per dose level. The intravenous infusions lasted 15 minutes and covered 4.21-140.45 nmol/kg. This was controlled single-dose research.
Pharmacokinetics describes what happens to the compound in the body; the hormone measurements describe the response it provoked. I prefer having those two questions together, because a drug concentration and a GH concentration are different readings. Neither supplies a personal dose for sleep, recovery or physique goals.
Half-life and GH timing
The same human IV study estimated a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg and a steady-state distribution volume of 0.22 L/kg. The GH response was a single discrete pulse peaking at about 0.67 h, or 40 minutes, after dosing.
The two-hour figure describes elimination after intravenous exposure in healthy male volunteers. Moving that number into a claim about a subcutaneous routine adds an assumption. Published human pharmacokinetic characterization of that community route is absent from this record. That missing route data is the snag I cannot get past.
Exposures used for different questions
| Study setting | Route and exposure used in that study |
|---|---|
| Adults after bowel resection | 0.03 mg/kg IV twice daily for up to 7 days |
| Adult female rats, bone growth | 18, 90, and 450 μg/day subcutaneously, divided three times daily for 15 days |
| Rats, postoperative ileus | 0.1 or 1 mg/kg IV four times daily |
| Rats, gastric emptying | 0.014 and 0.14 μmol/kg IV |
| Ferrets, cisplatin-associated weight loss | 1-3 mg/kg intraperitoneally |
The spread reflects different species, routes and experimental questions. These are descriptions of study protocols. None establishes a human regimen for routine use.
CJC-1295 Ipamorelin dosage
The combination has no established evidence-based human dose in this literature. Community protocols are anecdotal accounts rather than clinical evidence; repeating their quantities would give them an authority they have not earned. The studies above concern Ipamorelin as a single agent. Combining it with CJC-1295 opens another question about exposure and safety.
CJC-1295 Ipamorelin reconstitution
A mass printed on a container cannot resolve the clinical questions around the material inside. Identity, sterility and a validated preparation for human administration remain separate requirements. This site provides no mixing volumes or injection instructions. The mechanism page explains why the two compounds are discussed together; the effects page covers the safety uncertainties.